CN103889427A - 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用 - Google Patents

1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用 Download PDF

Info

Publication number
CN103889427A
CN103889427A CN201180073318.7A CN201180073318A CN103889427A CN 103889427 A CN103889427 A CN 103889427A CN 201180073318 A CN201180073318 A CN 201180073318A CN 103889427 A CN103889427 A CN 103889427A
Authority
CN
China
Prior art keywords
dihydro
dioxo
quinazolin
methanesulfonamide
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180073318.7A
Other languages
English (en)
Chinese (zh)
Inventor
K·库彻
D·约翰斯
G·因贝特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103889427A publication Critical patent/CN103889427A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180073318.7A 2011-09-07 2011-09-07 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用 Pending CN103889427A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
CN103889427A true CN103889427A (zh) 2014-06-25

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180073318.7A Pending CN103889427A (zh) 2011-09-07 2011-09-07 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用

Country Status (10)

Country Link
EP (1) EP2753331A1 (https=)
JP (1) JP2014525474A (https=)
KR (1) KR20140071405A (https=)
CN (1) CN103889427A (https=)
AU (1) AU2011376333A1 (https=)
BR (1) BR112014005210A2 (https=)
CA (1) CA2846503A1 (https=)
IN (1) IN2014DN01791A (https=)
MX (1) MX2014002693A (https=)
WO (1) WO2013036224A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
MA43532A (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals Inc Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2549965A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
CA2549967A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
EP1677790A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYLAMIDE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US10786464B2 (en) * 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
EP2753331A1 (en) 2014-07-16
MX2014002693A (es) 2014-06-04
KR20140071405A (ko) 2014-06-11
AU2011376333A1 (en) 2014-03-13
JP2014525474A (ja) 2014-09-29
WO2013036224A1 (en) 2013-03-14
CA2846503A1 (en) 2013-03-14
BR112014005210A2 (pt) 2017-03-21
IN2014DN01791A (https=) 2015-05-15

Similar Documents

Publication Publication Date Title
TWI353835B (en) Novel methods for identifying improved, non-sedati
DE602004007225T2 (de) Methode zur behandlung von erkrankungen der unteren harnwege
DE60109589T2 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
US10111889B2 (en) Uses of ganaxolone
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
US9771335B2 (en) Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
RS56523B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US9505727B2 (en) Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels
JP2003520193A (ja) Ｒ（−）−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物
AU2014393490B2 (en) (S)-pirlindole or its pharmaceutically acceptable salts for use in medicine
CN103889427A (zh) 1h-喹唑啉-2,4-二酮用于预防或治疗光敏性癫痫的应用
EA023728B1 (ru) Терапевтическое средство от тревожных расстройств
CN108348524A (zh) 用于从中风恢复的方法和组合物
Herrling et al. D-CPPene (SDZ EAA-494)—a competitive NMDA antagonist: pharmacology and results in humans
CN111050800B (zh) 血清素3受体激动剂对疼痛的治疗
CA3176643A1 (en) Use of dopamine d3 partial agonists for treating central nervous system disorders
JP2005314347A (ja) 疼痛抑制剤
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3
JP4362457B2 (ja) 神経因性疼痛治療剤
Hemanthkumar Study of anticonvulsant activity of acetazolamide on albino rats and its influence on anticonvulsant activity of sodium valproate
KR20120052341A (ko) 신경 세로이드 리포푸스신증의 치료에 사용하기 위한 1ｈ-퀴나졸린-2,4-디온
JP2025502526A (ja) てんかんにおける突然の予期せぬ死に関連する疾患を治療するためのセロトニン５－ｈｔ１ａ受容体アゴニストの使用
WO2015028673A1 (en) Cav3 CHANNEL BLOCKING AGENT FOR PAIN TREATMENT
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140625